ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01324479
Recruitment Status : Completed
First Posted : March 29, 2011
Last Update Posted : March 23, 2018
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: INC280 Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 131 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Open-label Dose Escalation Study With Expansion to Assess the Safety and Tolerability of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Actual Study Start Date : February 29, 2012
Actual Primary Completion Date : July 4, 2017
Actual Study Completion Date : July 4, 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: INC280 Drug: INC280



Primary Outcome Measures :
  1. Incidence rate of dose-limiting toxicities and adverse events [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Objective response by local investigator assessment [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have evidence of c-MET dysregulation from either local data or the results of molecular pre-screening evaluations.
  • Confirmed diagnosis of a solid tumor.
  • Measureable lesion.
  • Refractory to currently available treatment or no therapies available.
  • 18 years or older.
  • ECOG performance status of 0, 1, or 2.
  • Obtained written informed consent.

Additional inclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

  • Written documentation of EGFRwt NSCLC.
  • Written documentation of c-MET positivity.
  • Patients should not have received more than three prior lines of antineoplastic therapy for NSCLC.
  • Presence of at least one measurable lesion as determined by modified RECIST version 1.1

Exclusion Criteria:

HCC with liver dysfunction greater than Child-Pugh A. Previous treatment with a c-MET inhibitor or HGF-targeting therapy. Symptomatic CNS metastases that are neurologically unstable or requiring increasing doses of steroids to control their CNS disease.

Any CNS deficits. For patients with GBM, CNS symptoms grade 2 or greater. Subjects with significant or uncontrolled cardiovascular disease (eg, uncontrolled hypertension, peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute coronary syndrome) within 6 months of starting study treatment or heart attack within 12 months of starting study treatment.

Receiving anti-epileptic drugs that are known to be strong inducers of CYP3A4. Prior or current anti-angiogenic therapy for patients with GBM. Radiation therapy within ≤ 4 weeks (< 12 for GBM) prior to the first dose of study drug or limited field radiotherapy within ≤ 2 weeks (< 12 weeks GBM) prior to the start of study treatment. Any persistent side effect of prior radiotherapy must be resolved to ≤ Grade 1 prior to the first dose of study drug.

Additional exclusion criteria for NSCLC patients EGFRwt with high c-MET expression:

  • Patients who have received more than three prior lines of antineoplastic therapies
  • Any unresolved toxicity (CTCAE grade > 1) from previous anti-cancer therapy or radiotherapy, except alopecia
  • Patients have received anti-cancer therapies within the following time frames prior to the first dose of study treatment:

    • Conventional cytotoxic chemotherapy: ≤4 weeks (≤6 weeks for nitrosoureas and mitomycin-C)
    • Biologic therapy (e.g., antibodies): ≤4 weeks
    • Non-cytotoxic small molecule therapeutics: ≤5 half-lives or ≤2 weeks (whichever is longer)
    • Other investigational agents: ≤4 weeks
    • Radiation therapy (palliative setting is allowed.): ≤4 weeks
    • Major surgery: ≤2 weeks

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01324479


  Show 45 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01324479     History of Changes
Other Study ID Numbers: CINC280X2102
2010-024101-12 ( EudraCT Number )
First Posted: March 29, 2011    Key Record Dates
Last Update Posted: March 23, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Non-small cell lung cancer,
hepatocellular,
gastric,
renal cell,
c-MET,
refractory,
glioblastoma,
breast,
nasopharyngeal,
confirmed evidence of c-MET dysregulation